切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2022, Vol. 11 ›› Issue (06): 537 -541. doi: 10.3877/cma.j.issn.2095-3232.2022.06.001

述评

不可切除肝内胆管细胞癌转化治疗策略
方诚1, 夏勇1, 沈锋1,()   
  1. 1. 200438 上海,海军军医大学第三附属医院肝外四科
  • 收稿日期:2022-08-25 出版日期:2022-12-10
  • 通信作者: 沈锋
  • 基金资助:
    上海市临床重点专科建设项目(shslczdzk02402); 上海市申康医院发展中心项目(SHDC2020CR5007)

Conversion therapy strategies for unresectable intrahepatic cholangiocarcinoma

Cheng Fang1, Yong Xia1, Feng Shen1()   

  • Received:2022-08-25 Published:2022-12-10
  • Corresponding author: Feng Shen

肝内胆管细胞癌(ICC)是肝脏的第二大恶性肿瘤,发病率仅次于肝细胞癌,占肝脏肿瘤的10%~25%,我国ICC发病率7.45~7.55/10万[1,2]。ICC的发病机制尚不明确,炎症-肿瘤机制、干细胞起源假说等均可能是其重要潜在机制。目前认为肝内胆管结石、原发性硬化性胆管炎、病毒性肝炎、先天性胆道异常、毒性物质和职业暴露等均与ICC的发病相关[3]。手术切除仍是ICC最有效的治疗方式,术后5年生存率20%~40%,而无法手术的患者5年生存率仅为5%~10%[4,5]。由于ICC早期症状缺乏特异性,且易出现淋巴结转移和血管侵犯,大部分患者因腹痛、黄疸等就诊时已失去手术机会,根治性手术切除率仅为30%[6]。因此,提高手术切除率是改善ICC患者生存率的重要途径。

[1]
Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5):52.
[2]
Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3):1073274817729245.
[3]
Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6):1215-1229.
[4]
Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565.
[5]
Kamarajah S, Giovinazzo F, Roberts KJ, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis[J]. Ann Hepatobiliary Pancreat Surg, 2020, 24(1):6-16.
[6]
Buettner S, Galjart B, van Vugt JLA, et al. Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2017, 116(8):1085-1095.
[7]
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(6):600-616.
[8]
王之伟, 郑俊玲, 李江涛, 等. 肝内胆管癌的转化治疗[J]. 生物医学转化, 2020, (1) 26-34.
[9]
Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB, 2015, 17(8):669-680.
[10]
吴军, 琴瀚姣, 盛基尧, 等. 不可切除肝内胆管细胞癌诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2021, 10(1):1-5.
[11]
李起, 张瑞, 张景玮, 等. 术前外周血肝纤维化血清学指标对肝内胆管癌预后预测价值研究[J]. 中国实用外科杂志, 2021, 41(7):778-785.
[12]
Fong ZV, Brownlee SA, Qadan M, et al. The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines[J]. Ann Surg Oncol, 2021, 28(5):2660-2674.
[13]
Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(10): 3729-3737.
[14]
Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, andnab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
[15]
Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2):364-377.
[16]
Bekaii-Saab TS, Valle JW, Van Cutsem E, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements[J]. Future Oncol, 2020, 16(30):2385-2399.
[17]
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6):796-807.
[18]
Loaiza-Bonilla A, Clayton E, Furth E, et al. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine[J]. Ecancermedicalscience, 2014(8):479.
[19]
Ricci AD, Rizzo A, Bonucci C, et al. PARP inhibitors in biliary tract cancer: a new kid on the block?[J]. Medicines, 2020, 7(9):54.
[20]
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8):773-779.
[21]
Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from aphaseⅡstudy[J]. J Immunother Cancer, 2020, 8(1):e000367.
[22]
Zhang Q, Liu X, Wei S, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phaseⅡstudy[J]. Front Oncol, 2021(11): 751391.
[23]
Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma[J]. Strahlenther Onkol, 2017, 193(8):620-629.
[24]
Liu X, Yao J, Song L, et al. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade[J]. J Immunother Cancer, 2019, 7(1):204.
[25]
Liu ZL, Liu X, Peng H, et al. Anti-PD-1 immunotherapy and radiotherapy for stageⅣ intrahepatic cholangiocarcinoma: a case report[J]. Front Med, 2020(7):368.
[26]
Massani M, Bonariol L, Stecca T. Hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma, a comprehensive review[J]. J Clin Med, 2021, 10(12):2552.
[27]
Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122(5):758-765.
[28]
Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis[J]. Cardiovasc Intervent Radiol, 2021, 44(5):728-738.
[29]
Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment[J]. Ann Surg Oncol, 2015, 22(9):3102-3108.
[30]
Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1):51-59.
[31]
Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB, 2018, 20(12):1109-1118.
[32]
Vauthey JN, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement[J]. HPB, 2010, 12(5):289-299.
[33]
Piron L, Deshayes E, Escal L, et al. Portal vein embolization: present and future[J]. Bull Cancer, 2017, 104(5):407-416.
[34]
Li PP, Huang G, Jia NY, et al. Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study[J]. Hepatobiliary Surg Nutr, 2022, 11(1):38-51.
[35]
Li J, Moustafa M, Linecker M, et al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? an international multi-center study[J]. Ann Surg Oncol, 2020, 27(5):1372-1384.
[36]
Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873.
[37]
Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970.
[38]
Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3):965-981.
[39]
Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma[J]. Cancer Cell, 2017, 32(1):57-70, e53.
[40]
Dong L, Lu D, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell, 2022, 40(1):70-87, e15.
[41]
姜中豪, 戴朝六. 多学科综合治疗时代肝癌外科新理念[J/CD]. 中华普通外科学文献(电子版), 2020, 14(6):401-405.
[42]
Charriere B, Muscari F, Maulat C, et al. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings[J]. J Surg Oncol, 2017, 115(3):330-336.
[1] 匡铭, 梁力建. 肝癌外科治疗策略进展[J]. 中华普通外科学文献(电子版), 2022, 16(04): 307-307.
[2] 胡雄伟, 雷光林, 王森, 宋彪, 洪智贤. Laennec膜入路机器人肝右前叶(S5/8段)切除术[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 604-604.
[3] 曹李, 牛晓峰, 孟令展, 李虎, 于雁宾, 俞鹏, 严锦, 朱震宇. 同期肝切除联合脾切除在肝癌合并门静脉高压患者中的应用探讨[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 614-617.
[4] 胡斌, 赵伟, 宦宏波, 朱自满, 韩明明, 涂玉亮, 王大东, 蔡守旺. 以第三级肝蒂为主导的解剖性肝段切除与非解剖性肝切除对肝癌患者的疗效比较研究[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 618-621.
[5] 李新省, 张丽敏, 王烨, 冯宁宁, 焦志凯. 切缘宽度对原发性肝癌合并微血管侵犯患者并发症及预后的影响[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 622-626.
[6] 李磊, 周晓春, 李向利, 许磊, 姚一舟, 张睿. 前入路联合绕肝提拉法腹腔镜右肝巨大肿瘤切除术临床疗效研究[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 635-638.
[7] 赵国栋. 机器人肝内胆管细胞癌侵犯肝门部根治性切除术[J]. 中华普外科手术学杂志(电子版), 2022, 16(06): 603-603.
[8] 胡森焱, 徐冬, 陈功, 谢冬冬, 王财庆. 基于Takasaki分段法和Couinaud分段法的肝切除术治疗肝癌的效果对比研究[J]. 中华普外科手术学杂志(电子版), 2022, 16(04): 419-422.
[9] 周辉年, 李玉民. 肝癌转化治疗[J]. 中华肝脏外科手术学电子杂志, 2022, 11(06): 542-547.
[10] 黄华坤, 杨斌, 张起帆, 邓敬舵, 陈志, 程远. 腹腔镜大肝癌切除术安全性及有效性评估[J]. 中华肝脏外科手术学电子杂志, 2022, 11(06): 569-573.
[11] 刘文瑛, 欧阳再兴, 朱剑华, 吴黎明, 谭勇, 宋灏, 朱玉珍, 黄从云. 多模态影像技术在精准肝癌肝切除中的应用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(06): 574-579.
[12] 胡宇, 马金良, 葛勇胜, 余继海, 张传海, 刘文斌, 荚卫东. ICG荧光显像技术在肝癌腹腔镜肝切除术中应用的安全性及疗效[J]. 中华肝脏外科手术学电子杂志, 2022, 11(06): 580-585.
[13] 干宸鑫, 王兴, 潘耀振. 三维重建在中晚期肝癌转化切除中的应用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(05): 503-507.
[14] 倪海旭, 张宇泓, 张磊, 李汛. 深度学习在肝癌诊疗中的研究进展[J]. 中华肝脏外科手术学电子杂志, 2022, 11(05): 531-534.
[15] 陈剑尉, 洪跃飞, 何进达, 成俊, 王成友, 贾晨阳. 肝巨大血管瘤腹腔镜手术治疗策略及疗效[J]. 中华肝脏外科手术学电子杂志, 2022, 11(04): 406-410.
阅读次数
全文


摘要